Impulse control disorders in patients with dopamine agonist‐treated prolactinomas and nonfunctioning pituitary adenomas: a case–control study

Males with prolactinomas treated with DAs were 9·9 times more likely to develop an ICD than their counterparts with nonfunctioning pituitary adenomas. Until prospective studies on the relationship of DA use in patients with prolactinoma and ICDs are available, the authors propose that patients with prolactinoma be forewarned of possible ICD development with DA therapy.